In other studies, circulating serum levels of insulin-sensitizing adiponectin have been found to be lower in obesity, so future therapeutic tools will need to be developed to increase concentrations, and therefore, promote a healthier phenotype. This evidence concerns the gene ADIPOQ and obesity disorder.